Vedolizumab Maintenance Therapy for Crohnʼs Disease: Results of GEMINI II, a Randomized, Placebo-Controlled, Double-Blind, Multi-center Phase 3 Trial
Stephen B. Hanauer(Northwestern University), Asit Parikh, Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Milan Lukáš(Charles University), William J. Sandborn(University of San Diego), Paul Rutgeerts(KU Leuven), Richard Fedorak, Catherine Milch(Millennium Engineering and Integration (United States)), Kristin Stephens(Millennium Engineering and Integration (United States)), Brian Bressler(University of British Columbia), Scott D. Lee(University of Washington), Serap Sankoh(Millennium Engineering and Integration (United States)), Jing Xu(Kunming Medical University), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Brian G. Feagan(Western University), Irving H. Fox(Takeda (United States))
Cited by 5
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k